Clinical trials: Neoplasm Recurrence
Recurrent Glioblastoma Multiforme
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.
- Trial name
- NCT00071539
- Testing
- TP-38, TP38
- Volunteers
- 56 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Recurrent Ovarian Carcinoma
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with…
- Trial name
- NCT03353831
- Testing
- Bevacizumab, Atezolizumab, Chemotherapy
- Where
- 111 sites in Austria, Belgium and 10 more
- Volunteers
- 574 people
- Sponsor
- AGO Research GmbH
Chronic Lymphocytic Leukemia, CLL
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
TP-0903 is an inhibitor of AXL kinase. TP-0903 has shown potent inhibition of AXL kinase and other TAM family members in a biochemical kinase assay.
- Conditions
- Chronic Lymphocytic Leukemia, CLL, SLL, Small Lymphocytic Lymphoma
- Trial name
- NCT03572634
- Testing
- TP-0903, TP-0903 and ibrutinib combination therapy
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Sumitomo Pharma America, Inc.
Squamous Cell Carcinoma of Head and Neck
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants…
- Trial name
- OrigAMI-5 (NCT07276399)
- Testing
- Amivantamab, Pembrolizumab, Carboplatin
- Where
- 205 sites in United States, Australia and 20 more
- Volunteers
- 600 people
- Sponsor
- Janssen Research & Development, LLC
Ovarian Carcinoma, Recurrent Endometrial Carcinoma
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
The folate receptor is overexpressed in many types of cancer, including ovarian and endometrial cancer, and the level of folate receptor expression increases with the stage of the disease.
- Trial name
- NCT01689714
- Testing
- Tc 99m EC20
- Volunteers
- 16 people
- Sponsor
- Endocyte
Malignant Glioma, Glioblastoma Multiforme
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00024557
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study.
- Trial name
- NCT05038800
- Testing
- MK-0482
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Leukemias
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
- Trial name
- NCT01826214
- Testing
- LDE225
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Lymphoma
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma.
- Trial name
- NCT04464798
- Testing
- CC-220, Rituximab, Obinutuzumab
- Where
- 26 sites in United States, France and 4 more
- Volunteers
- 62 people
- Sponsor
- Celgene
Glioblastoma Multiforme
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following…
- Trial name
- NCT02047214
- Testing
- TPI 287, Bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cortice Biosciences, Inc.
Small Cell Lung Cancer
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
The purpose of this study is to determine whether INNO-206 is effective in the treatment of small cell lung cancer.
- Trial name
- NCT00472771
- Testing
- INNO-206
- Where
- 7 sites in United States
- Sponsor
- CytRx
Relapsed or Refractory Lymphoma
HMPL-523 Food Effect and Proton Pump Inhibitor Study
A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
- Trial name
- NCT05571787
- Testing
- HMPL-523, Rabeprazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety.
- Trial name
- NCT06786533
- Testing
- Anti-FLT3 CAR-T cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Hemogenyx Pharmaceuticals LLC
Mesothelioma, Malignant
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
- Trial name
- NCT05324436
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso
Ascites, Liver Cirrhosis
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary: To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites.
- Trial name
- SPARe-2 (NCT00366795)
- Testing
- Satavaptan
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 241 people
- Sponsor
- Sanofi
Malignant Mesothelioma
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether Onconase plus doxorubicin is more effective than doxorubicin alone in…
- Trial name
- NCT00003034
- Testing
- doxorubicin hydrochloride, ranpirnase
- Where
- 19 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Alfacell
Low Grade Serous Ovarian Cancer, Ovarian Cancer
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Trial name
- RAMP201J (NCT06682572)
- Testing
- Avutometinib (VS-6766) + Defactinib (VS-6063)
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Verastem, Inc.
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Trial name
- NCT05370430
- Testing
- BAFFR-CAR T cells
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- PeproMene Bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.